StockpollyBeta
Get App
Popularity #1,201
COGT · NASDAQ · Biotechnology

Cogent Biosciences (COGT)

Develops bezuclastinib and other mutation-targeted therapies for mast-cell disease and cancer.

$31.39
vs last close−1.25 (−3.82%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000010110
Gross profit0000000−10−1−10
60586264757475748398102103
Research & development504953546462636169747571
91010101212121314242832
General & administrative91010101212121314242832
Other expenses0000000000−10
Operating income−60−58−62−64−75−74−75−76−83−99−104−103
444556322−366
Interest income444554324587
Interest expense000000001111
Other non-operating income0−4−4−5−5−6−3−2−46−7−7
Income before tax−55−54−58−59−71−68−72−74−81−102−97−96
Net income from continuing operations−55−54−58−59−71−68−72−74−81−102−97−96
Net income−55−54−58−59−71−68−72−74−81−102−97−96
EPS, basic−$0.64−$0.63−$0.62−$0.59−$0.64−$0.61−$0.63−$0.65−$0.58−$0.64−$0.57−$0.52
EPS, diluted−$0.64−$0.63−$0.62−$0.59−$0.64−$0.61−$0.63−$0.65−$0.58−$0.64−$0.57−$0.52
Weighted average shares, basic86879599110110114114140161171171
Weighted average shares, diluted86879599110110114114140161171171
EBITDA−59−54−57−58−70−67−71−72−79−105−95−94
Depreciation & amortization111111111111
EBIT−60−54−58−59−71−68−72−73−79−106−96−95